65.43M
Market cap
Current P/E
Forward P/E

About

Health care
Sector
Biotechnology
Industry

DBV Technologies S. A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults.

Similar securities

Based on sector and market capitalization

Report issue